Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world,with estimates of non-alcoholic steatohepatitis(NASH)prevalence in over 25 percent of the world’s population.NASH r...Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world,with estimates of non-alcoholic steatohepatitis(NASH)prevalence in over 25 percent of the world’s population.NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual cirrhosis,with the risk of cirrhosis decompensation,and hepatocellular carcinoma.New therapies are desperately needed for NASH,especially for later stages of fibrosis and cirrhosis.Galectin-3 inhibition is being explored as a new liver antifibrotic therapy.This concise review will outline the state of the art of this new therapeutic target.展开更多
基金The author acknowledges Dr.Pol Boudes for reviewing this manuscript and Dr.Zachary Goodman for providing the galectin-3 antibody histological images.
文摘Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world,with estimates of non-alcoholic steatohepatitis(NASH)prevalence in over 25 percent of the world’s population.NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual cirrhosis,with the risk of cirrhosis decompensation,and hepatocellular carcinoma.New therapies are desperately needed for NASH,especially for later stages of fibrosis and cirrhosis.Galectin-3 inhibition is being explored as a new liver antifibrotic therapy.This concise review will outline the state of the art of this new therapeutic target.
